Brief: Medicenna Therapeutics Reports Q3 Fiscal 2024 Financial Results
14/02/2024 13:34
Feb 14 (Reuters) - Medicenna Therapeutics Corp
MDNA.TO :
* MEDICENNA THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2024
FINANCIAL RESULTS AND CORPORATE UPDATE
* CASH RUNWAY EXTENDED THROUGH MULTIPLE DATA READOUTS AND
INTO Q2
OF CALENDAR 2025
* NET LOSS FOR QUARTER ENDED DECEMBER 31, 2023, WAS $5.0
MILLION
OR $0.07 LOSS PER SHARE
Source text for Eikon: ID:nGNX8d7d8W
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results